ERNA
Ernexa Therapeutics Inc
$
1.680
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.7387
Open
1.690
VWAP
1.69
Vol
21.11K
Mkt Cap
12.37M
Low
1.6177
Amount
35.60K
EV/EBITDA(TTM)
--
Total Shares
5.41M
EV
12.77M
EV/OCF(TTM)
--
P/S(TTM)
80.50
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Show More
Valuation Metrics
The current forward P/E ratio for Ernexa Therapeutics Inc (ERNA.O) is -0.01, compared to its 5-year average forward P/E of -3.48. For a more detailed relative valuation and DCF analysis to assess Ernexa Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.48
Current PE
-0.01
Overvalued PE
3.47
Undervalued PE
-10.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
-52.83%
-2.73M
Operating Profit
FY2025Q1
YoY :
+23.39%
-8.20M
Net Income after Tax
FY2025Q1
YoY :
-87.80%
-0.15
EPS - Diluted
FY2025Q1
YoY :
-46.34%
-2.07M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
-2.70K
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 463.67% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
2.2M
USD
Months
3-6
1
394.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 463.67% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
2.2M
USD
Months
3-6
1
394.2K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ERNA News & Events
Events Timeline
2025-07-09 (ET)
2025-07-09
08:38:03
Ernexa Therapeutics regains compliance with Nasdaq listing rules
2025-06-25 (ET)
2025-06-25
08:35:49
Ernexa Therapeutics expands Scientific Advisory Board
2025-06-24 (ET)
2025-06-24
08:42:50
Ernexa secures $6M in second closing under securities purchase agreement
Sign Up For More Events
Sign Up For More Events
News
5.0
06-25NewsfilterErnexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
5.0
06-12NASDAQ.COMInsider Purchase: 10% owner at $ERNA Buys 21,241,163 Shares
7.0
06-10NASDAQ.COMErnexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance
Sign Up For More News
People Also Watch
DRCT
Direct Digital Holdings Inc
0.484
USD
-18.49%
INHD
Inno Holdings Inc
1.250
USD
+3.30%
PSHG
Performance Shipping Inc
1.830
USD
+9.58%
SFHG
Samfine Creation Holdings Group Ltd
0.800
USD
+2.56%
SHFS
SHF Holdings Inc
2.460
USD
-2.77%
SNTI
Senti Biosciences Inc
1.690
USD
-1.74%
CDIO
Cardio Diagnostics Holdings Inc
3.940
USD
-1.01%
NWGL
Nature Wood Group Ltd
1.105
USD
-1.34%
INAB
IN8bio Inc
2.100
USD
-3.23%
ELBM
Electra Battery Materials Corp
1.145
USD
-1.29%
FAQ
What is Ernexa Therapeutics Inc (ERNA) stock price today?
The current price of ERNA is 1.68 USD — it has decreased -0.59 % in the last trading day.
What is Ernexa Therapeutics Inc (ERNA)'s business?
What is the price predicton of ERNA Stock?
What is Ernexa Therapeutics Inc (ERNA)'s revenue for the last quarter?
What is Ernexa Therapeutics Inc (ERNA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ernexa Therapeutics Inc (ERNA)'s fundamentals?
How many employees does Ernexa Therapeutics Inc (ERNA). have?